期刊文献+

初治急性白血病应用氟康唑预防真菌感染的临床观察 被引量:2

Clinical observation on prevention of fungal infection in primary acute leukemia with fluconazole
暂未订购
导出
摘要 目的观察氟康唑在初治急性白血病(AL)患者粒细胞缺乏期预防真菌感染的疗效。方法回顾性分析本院2007年1月~2013年1月住院的58例初治AL患者,将其分为治疗组与对照组,治疗组给予氟康唑胶囊100 mg/d,口服,白化疗开始至脱离粒细胞缺乏时停止;对照组未常规应用预防性抗真菌治疗。观察两组患者真菌感染率的差异。结果治疗组化疗后并发真菌感染率为7.4%(2/27),对照组并发真菌感染率为29.0%(9/31),差异有统计学意义(P<0.05)。结论氟康唑预防性治疗对于预防初治AL患者真菌感染有显著疗效。 Objective To evaluate the efficacy of fluconazole for prevention of fungal infection in neutropenia patients with primary acute leukemia after chemotherapy.Methods Clinical data of 58 patients with acute leukemia in our hos- pital from January 2007 to January 2013 were retrospectively analyzed,all the patients were divided into treatment group and control group.Patients in treatment group received fluconazole (100 mg/d) after chemotherapy until out of neutropenic.The patients in control group were not received the prophylactic antifungal therapy.The difference of the incidence of fungal infection between the tow groups was observed. Results The rate of fungal infection in treatment group was 7.4%(2/27),and 29.0%(9/31) in control group.The difference was statistically significant (P〈0.05). Conclu- sion The prophylactic treatment with fluconazole can effectively reduce the incidence of fungal infections in neutrope- nia patients with acute leukemia after chemotherapy.
出处 《中国当代医药》 2013年第20期87-88,共2页 China Modern Medicine
关键词 氟康唑 预防 急性白血病 真菌感染 Fluconazole Prevention Acute leukemia Fungal infection
  • 相关文献

二级参考文献16

  • 1黄晓军.血液病/恶性肿瘤患者侵袭性真菌感染的诊断标准与治疗原则(草案)[J].中华内科杂志,2005,44(7):554-556. 被引量:424
  • 2王景枝,刘代红,许兰平,陈欢,刘开彦,黄晓军.伊曲康唑在异基因造血干细胞移植患者真菌感染中的应用[J].中华内科杂志,2007,46(1):29-31. 被引量:7
  • 3血液病/恶性肿瘤患者侵袭性真菌感染的诊断标准与治疗原则(修订版)[J].中华内科杂志,2007,46(7):607-610. 被引量:251
  • 4Ellis M.Invasive fungal infections:evolving challenges for diagnosis and therapeutics[J].Mol Immunol,2001,38:947-957.
  • 5Kieren AM,Thomas P,David D,et al.Aspergillosis:pathogenesis,clinical manifestation and therapy[J].Infect Dis Clin N Am,2002,16:875-894.
  • 6Ostroskky-ZeichnerL.New approaches to the risk of candida in the intensive care unit[J].Curr Opin Infect Dis,2003,16:533-537.
  • 7Wong-beringer A,Kriengkauykiat J.Systemic antifungal therapy:new options,new challenges[J].Pharmacotherapy,2003,23:1441-1462.
  • 8Herbrecht R,Denning DW,Patterson TF,et al.Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.N EnglJ Med,2002,347:408-415.
  • 9Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis, 2002, 34: 7-14.
  • 10Bohme A, Ruhnke M, Buchheidt D, et al. Treatment of fungal infections in hematology and oncology-guidelines of the Infectious Diseases Working Party (AG1HO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol, 2003, 82 Suppl 2 :S133-S140.

共引文献871

同被引文献15

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部